Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.02 USD
-0.10 (-2.43%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $4.02 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value D Growth F Momentum D VGM
Company Summary
Cambridge, MA-based Ironwood Pharmaceuticals, Inc. is focused on the development and commercialization of treatments primarily addressing gastrointestinal (GI) diseases.
Linzess (linaclotide) is marketed in collaboration with Allergan (now a subsidiary of AbbVie) for patients suffering from irritable bowel syndrome with constipation (IBS-C; 290 mcg) or chronic idiopathic constipation (CIC; 145 mcg & 72 mcg).
Ironwood and AbbVie co-develop and co-commercialize Linzess and equally share Linzess' U.S. collaboration profits or losses as well as all development costs. Linzess is marketed by AbbVie for IBS-C in Europe and Canada under ...
Company Summary
Cambridge, MA-based Ironwood Pharmaceuticals, Inc. is focused on the development and commercialization of treatments primarily addressing gastrointestinal (GI) diseases.
Linzess (linaclotide) is marketed in collaboration with Allergan (now a subsidiary of AbbVie) for patients suffering from irritable bowel syndrome with constipation (IBS-C; 290 mcg) or chronic idiopathic constipation (CIC; 145 mcg & 72 mcg).
Ironwood and AbbVie co-develop and co-commercialize Linzess and equally share Linzess' U.S. collaboration profits or losses as well as all development costs. Linzess is marketed by AbbVie for IBS-C in Europe and Canada under the brand name Constella. Ironwood receives royalties on sales of Constella in Europe and Canada from AbbVie.
In Japan, Ironwood has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong and Macau. Linzess received approval for IBS-C indication in Japan in December 2016 and for chronic constipation (CC) in August 2018. In January 2019, the drug was approved in China for IBS-C.
The FDA approved the expanded use of Linzess for pediatric functional constipation (FC) in June 2023.
The company spun off its soluble guanylate cyclase (sGC) segment into a separate, publicly traded company, Cyclerion Therapeutics, in 2019.
Ironwood’s revenues in 2023 increased 7.8% year over year to $442.7 million. Collaboration revenues from Linzess increased 7.9% year over year to $430.5 million.
General Information
Ironwood Pharmaceuticals, Inc
100 SUMMER STREET SUITE 2300
BOSTON, MA 02110
Phone: 617-621-7722
Fax: 617-494-0480
Web: http://www.ironwoodpharma.com
Email: gmartini@ironwoodpharma.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/14/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.08 |
Current Year EPS Consensus Estimate | 0.24 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/14/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 4.12 |
52 Week High | 15.70 |
52 Week Low | 3.79 |
Beta | 0.48 |
20 Day Moving Average | 2,071,267.75 |
Target Price Consensus | 11.43 |
4 Week | -18.58 |
12 Week | -37.29 |
YTD | -63.99 |
4 Week | -20.19 |
12 Week | -39.35 |
YTD | -70.19 |
Shares Outstanding (millions) | 159.74 |
Market Capitalization (millions) | 658.13 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 17.17 |
Trailing 12 Months | 41.20 |
PEG Ratio | NA |
vs. Previous Year | -100.00% |
vs. Previous Quarter | 100.00% |
vs. Previous Year | -12.09% |
vs. Previous Quarter | 26.07% |
Price/Book | NA |
Price/Cash Flow | NA |
Price / Sales | 1.64 |
6/30/24 | -6.37 |
3/31/24 | -28.45 |
12/31/23 | -185.45 |
6/30/24 | 4.61 |
3/31/24 | 18.84 |
12/31/23 | 21.00 |
6/30/24 | 3.92 |
3/31/24 | 0.82 |
12/31/23 | 0.84 |
6/30/24 | 3.92 |
3/31/24 | 0.82 |
12/31/23 | 0.84 |
6/30/24 | 5.26 |
3/31/24 | 23.21 |
12/31/23 | 32.66 |
6/30/24 | 2.30 |
3/31/24 | -254.41 |
12/31/23 | -226.37 |
6/30/24 | 21.50 |
3/31/24 | -243.98 |
12/31/23 | -214.14 |
6/30/24 | -2.01 |
3/31/24 | -2.11 |
12/31/23 | -2.21 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |